TRMD 690 Seminar:Neogenin 1 as a Novel Potential Predictive Biomarker to Ameliorate NSCLC Immunotherapy Resistance”, Asmita Pandey, PhD Student

When

04/19/2023    
12:00 PM - 1:00 PM

Where

JABSOM Medical Education Bldg., Rm. 304
651 Ilalo St., Honolulu,, HI

Event Type

In-Person and By Zoom

Zoom ID: 979 6297 5142

Contact corit@hawaii.edu for passcode

 

Asmita Pandey
Ph.D. Student
Department of Tropical Medicine, Medical Microbiology and Pharmacology
John A. Burns School of Medicine
University of Hawaii at Manoa


Non-small cell lung cancer (NSCLC) has a poor survival rate due to delayed diagnosis and treatment resistance. Immunotherapies have advanced the NSCLC treatment at present, however, only a small fraction of patients respond to the therapy, which necessitates to identify biomarkers that play a role in therapy resistance. From the list of anti-PD1/PD-L1 treatment resistance-associated biomarkers, identified by studies done in our lab, we discovered that Neogenin 1 (Neo1) shows relatively high expression in the NSCLC patients that leads to increased resistance. We hypothesized that high expression of Neo1 in NSCLC patients downregulates PD1/PD-L1 expression leading to the treatment resistance. To validate this, we plan to perform Neo1 manipulation in NSCLC and jurkat T cells to measure the effect on PD1/PD-L1 expression, following the investigation of the anti-PD1/PD-L1 treatment response in co-culture environment. In future, our goal is to explore the mechanism on how Neo1 overexpression regulates PD1/PD-L1 expression.